AbbVie Inc (ABBV)vsPrivia Health Group Inc (PRVA)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
PRVA
Privia Health Group Inc
$24.69
-0.60%
HEALTHCARE · Cap: $3.10B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2781% more annual revenue ($61.16B vs $2.12B). ABBV leads profitability with a 6.9% profit margin vs 1.1%. ABBV trades at a lower P/E of 100.0x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
PRVA
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
+70.2%
Fair Value
$72.49
Current Price
$24.69
$47.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Earnings expanding 132.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
17.4% revenue growth
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
ROE of 4.0% — below average capital efficiency
1.1% margin — thin
Operating margin of 2.1%
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : PRVA
The strongest argument for PRVA centers on EPS Growth, Debt/Equity, Altman Z-Score. Revenue growth of 17.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : PRVA
The primary concerns for PRVA are Return on Equity, Profit Margin, Operating Margin. A P/E of 137.2x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while PRVA is a growth play — different risk/reward profiles.
PRVA carries more volatility with a beta of 0.87 — expect wider price swings.
PRVA is growing revenue faster at 17.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 48/100). PRVA offers better value entry with a 70.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Privia Health Group Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Privia Health Group, Inc. is a population health technology and medical practice management company in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?